RIGEL PHARMACEUTICALS, INC. (RIGL) Return on equity 2016–2025
RIGEL PHARMACEUTICALS, INC. (RIGL) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
93.8%FY2025 · since FY2016: -125.8% → 93.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 93.8% | -438.0 pp |
| FY2024 | 531.8% | — |
| FY2021 | -59.0% | +28.4 pp |
| FY2020 | -87.4% | +36.9 pp |
| FY2019 | -124.3% | -60.2 pp |
| FY2018 | -64.1% | +13.3 pp |
| FY2017 | -77.5% | +48.3 pp |
| FY2016 | -125.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RIGL financial trends
RIGL RevenueRIGL Net incomeRIGL Net marginRIGL Gross profitRIGL Gross marginRIGL Operating incomeRIGL Operating marginRIGL Operating cash flowRIGL Free cash flowRIGL Capital expendituresRIGL Stock buybacksRIGL Dividends paidRIGL Total assetsRIGL Total liabilitiesRIGL Shareholders’ equityRIGL overview →